Clinical, pathological and molecular characteristics of patients with primary lung cancer who attended the thoracic oncology expert center at Fundación Neumológica Colombiana
Article Sidebar
Main Article Content
Abstract
Introduction: Lung cancer patients have rarely been characterized in Colombia.
Methods: This cross-sectional study describes all patients with non-hematolymphoid primary lung malignancies who attended the thoracic oncology expert center at Fundación Neumológica Colombiana between January 2019 and August 2023. Demographics, risk factors, comorbidities, lung function, histology, staging, and time to diagnosis and treatment were evaluated. Additionally, genomic profiling and PD-L1 expression were assessed in patients with Non-Small Cell Lung Cancer (NSCLC).
Results: Of 163 patients with primary lung cancer, 59.5% were women and 49.7% had no history of tobacco consumption. 41.7% had a cardiopulmonary comorbidity. NSCLC accounted for 88.3%, neuroendocrine tumors 6.7% and neuroendocrine carcinomas 4.3%. 31.2 % of NSCLC were stage I or II and 43.1 % were stage IV. A targetable mutation was found in 51.9% (42/81) of patients with NSCLC tested for at least one of them. EGFR mutations were found in 42.0% (34/81) of patients tested, making it the most frequent targetable mutation. The median time to diagnosis was 54 days and to treatment was 46 days.
Conclusions: Female sex, absence of tobacco consumption history and targetable mutations were more frequent than previously reported in Colombia. The time to diagnosis and treatment was longer than estimated by local government agencies.
Downloads
Article Details
Section
This work is licensed under a Creative Commons Attribution 4.0 International License.
How to Cite
References
Globocan: International Agency for Research on Cancer. Colombia fact sheet 2020 [Internet]. [Consultado 18 feb 2025]. Disponible en: https://gco.iarc.who.int/media/globocan/factsheets/populations/170-colombia-fact-sheet.pdf
Fondo Colombiano de Enfermedades de Alto Costo Cuenta de Alto Costo [CAC]. Indicadores de gestión del riesgo en pacientes con cáncer de pulmón en Colombia, Bogotá D.C.; 2018. [Internet]. [Consultado 9 ago 2025]. Disponible en: https://cuentadealtocosto.org/consenso-basado-en-la-evidencia-indicadores-de-gestion-del-riesgo-en-pacientes-con-cancer-de-pulmon-en-colombia/
Nicholson AG, Tsao MS, Beasley MB, Borczuk AC, Brambilla E, Cooper WA et al. The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015. J Thorac Oncol 2022;17(3):362–87. https://doi.org/10.1016/j.jtho.2021.11.003
Bazhenova L, Ismaila N, Abu Rous F, Alluri K, Freeman-Daily J, Halmos B et al. Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.2. J Clin Oncol 2024;42(36):e72–86. https://doi.org/10.1200/jco-24-02133
Martínez C, Morón F, Meléndez P. Síntomas respiratorios en pacientes con cáncer pulmonar: una comparación del tiempo de consulta entre fumadores y no fumadores. Rev Colomb Neumol 2003;15(3):105–9. https://doi.org/10.30789/rcneumologia.v15.n3.2003.1245
Alvarado-Sarzosa F, Martinez-Jaramillo SI, García-Herreros-Hellal LG, Beltrán-Jimenez RJ, Zuluaga-Restrepo JD, Parra-Medina R et al. Desenlaces clínicos de pacientes con cáncer de pulmón de célula no pequeña temprano manejados quirúrgicamente en Bogotá. Rev Colomb Cancerol 2023;27(2):240–50. https://doi.org/10.35509/01239015.904
Otero JM, Cardona AF, Revéiz L, Campo F, Carranza H, Vargas CA et al. Supervivencia en pacientes con adenocarcinoma de pulmón metastásico y registro de las primeras mutaciones en el receptor para el factor de crecimiento epidérmico documentado en Colombia Estudio del ONCOLGroup. Acta Médica Colombiana 2009;34(2):55–65.
Lema M, Preciado B, Lema C, Rodríguez D, Pineda M, Egurrola J et al. Survival Outcomes in Advanced Non-Small Cell Lung Cancer in a Cancer Center in Medellin - Colombia. CES Medicina 2023;37(1):44–57. https://doi.org/10.21615/cesmedicina.7186
Martin C, Cuello M, Barajas O, Recondo G, Aruachan S, Perroud H et al. Real-world evaluation of molecular testing and treatment patterns for EGFR mutations in non-small cell lung cancer in Latin America. Mol Clin Oncol 2022;16(6):1–10. https://doi.org/10.3892/mco.2021.2439
Alarcón ML, Brugés R, Carvajal C, Vallejo C, Beltrán R. Características de los pacientes con cáncer de pulmón de célula no pequeña en el Instituto Nacional de Cancerología de Bogotá. Rev Col Cancerol 2021;25(2):103–9. https://doi.org/10.35509/01239015.706
Fondo Colombiano de Enfermedades de Alto Costo Cuenta de Alto Costo (CAC). Situación del cáncer en la población adulta atendida en el SGSSS de Colombia 2022. Bogotá, D.C.; 2023.
Fu Y, Liu J, Chen Y, Liu Z, Xia H, Xu H. Gender disparities in lung cancer incidence in the United States during 2001–2019. Sci Rep 2023;13(12581):1–14. https://doi.org/10.1038/s41598-023-39440-8
Huang C, Qu X, Du J. Proportion of lung adenocarcinoma in female never-smokers has increased dramatically over the past 28 years. J Thorac Dis 2019;11:2685–8. https://doi.org/10.21037/jtd.2019.07.08
Siegel DA, Fedewa SA, Henley SJ, Pollack LA, Jemal A. Proportion of Never Smokers Among Men and Women With Lung Cancer in 7 US States. JAMA Oncol 2021;7(2):302–4. https://doi.org/10.1001/jamaoncol.2020.6362
Shiels MS, Graubard BI, McNeel TS, Kahle L, Freedman ND. Trends in smoking-attributable and smoking-unrelated lung cancer death rates in the United States, 1991-2018. JNCI 2023;0(0):1–6. https://doi.org/10.1093/jnci/djad256
Adams SJ, Stone E, Baldwin DR, Vliegenthart R, Lee P, Fintelmann FJ. Lung cancer screening. The Lancet 2023;401(10374):390–408. https://doi.org/10.1016/S0140-6736(22)01694-4
Chang GC, Chiu CH, Yu CJ, Chang YC, Chang YH, Hsu KH et al. Low-dose CT screening among never-smokers with or without a family history of lung cancer in Taiwan: a prospective cohort study. Lancet Respir Med 2024;12(2):141–52. https://doi.org/10.1016/S2213-2600(23)00338-7
Franco F, Carcereny E, Guirado M, Ortega AL, López-Castro R, Rodríguez-Abreu D et al. Epidemiology, treatment, and survival in small cell lung cancer in Spain: Data from the thoracic tumor registry. PLoS One 2021;16(6):e0251761. https://doi.org/10.1371/journal.pone.0251761
Taboada Barrios LB, López Panqueva R del P, García-Herreros Hellal LG, Gonzalez Devia D. Experiencia diagnóstica de diez años del tumor neuroendocrino de pulmón en la Fundación Santafé de Bogotá 2001-2010. Rev Col Neumol 2001;24(2):84–91. https://doi.org/10.30789/rcneumologia.v24.n2.2012.189
Papaxoinis G, Lamarca A, Quinn AM, Mansoor W, Nonaka D. Clinical and Pathologic Characteristics of Pulmonary Carcinoid Tumors in Central and Peripheral Locations. Endocr Pathol 2018;29:259–68. https://doi.org/10.1007/s12022-018-9530-y
Arrieta O, Cardona AF, Martín C, Más-López L, Corrales-Rodríguez L, Bramuglia G et al. Updated frequency of EGFR and KRAS mutations in NonSmall-cell lung cancer in Latin America: The Latin-American consortium for the investigation of lung cancer (CLICaP). J Thorac Oncol 2015;10(5):838–43. https://doi.org/10.1097/JTO.0000000000000481
Lynch C, Harrison S, Butler J, Baldwin DR, Dawkins P, van der Horst J et al. An International Consensus on Actions to Improve Lung Cancer Survival: A Modified Delphi Method Among Clinical Experts in the International Cancer Benchmarking Partnership. Cancer Control 2022;29. https://doi.org/10.1177/10732748221119354
Labbé C, Anderson M, Simard Msc S, Tremblay L, Laberge F, Vaillancourt R et al. Wait times for diagnosis and treatment of lung cancer: A single-centre experience. Current Oncology 2017;24(6):367–73. https://doi.org/10.3747/co.24.3655